Benzinga
Benzinga
Benzinga
lundi, septembre 14

Clover Health Investments Corp

CLOVNASDAQ
Trade with Public
Trade with Public
$4.82
0.112.34%
À la clôture: Sep 10, 5:00 PM EST
$4.85
0.142.97%
Pré-ouverture: 4:32 AM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerRapport sur les stocks

Clover Health Investments Analyst Price Targets

Wall Street analyst price targets and consensus rating for Clover Health Investments (CLOV).

Price Target Range — 7 Quarters

Analyst Consensus — 4 Analysts

2Buy
2Hold
Consensus RatingBuy# Analysts4Avg. Consensus PT$5Upside to Avg. PT-2.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →
DateFirmAnalystActionRating ChangePrice Target
Aug 6, 2026UBSJonathan YongPT RaiseNeutral$5→$5
Jul 21, 2026Canaccord GenuityRichard ClosePT RaiseBuy$4→$6
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Maintains Neutral on Clover Health Investments, Raises Price Target to $5

UBS analyst Jonathan Yong maintains Clover Health Investments (NASDAQ:CLOV) with a Neutral and raises the price target from $4.75 to $5.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $5.5

Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and raises the price target from $4.2 to $5.5.
Benzinga Newsdesk

PRO
UBS Maintains Neutral on Clover Health Investments, Raises Price Target to $4.75

UBS analyst Jonathan Yong maintains Clover Health Investments (NASDAQ:CLOV) with a Neutral and raises the price target from $2.75 to $4.75.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $4.2

Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and raises the price target from $3.2 to $4.2.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Lowers Price Target to $3.2

Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and lowers the price target from $3.7 to $3.2.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Maintains $3.7 Price Target

Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and maintains $3.7 price target.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved